Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

BACKGROUND: The aim of this study was to project health-economic outcomes relevant to the German setting for the addition of pioglitazone to existing treatment regimens in patients with type 2 diabetes, evidence of macrovascular disease and at high risk of cardiovascular events. METHODS: Event rates...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Scherbaum, Werner A, Goodall, Gordon, Erny-Albrecht, Katrina M, Massi-Benedetti, Massimo, Erdmann, Erland, Valentine, William J
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2009
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2688482/
https://ncbi.nlm.nih.gov/pubmed/19416529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1478-7547-7-9
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg